Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M476Revenue $M26.3Net Margin (%)-759.4Altman Z-Score-3.1
Enterprise Value $M322EPS $-5.5Operating Margin %-734.4Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-760.9Higher ROA y-yN
Price/Book11.710-y EBITDA Growth Rate %--Quick Ratio2.3Cash flow > EarningsN
Price/Sales3.85-y EBITDA Growth Rate %--Current Ratio2.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-108.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-1,105.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M38.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CHRS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CHRSGeorge Soros 2015-06-30 Buy 0.04%$21.07 - $30.58
($25.36)
$ 12.54-51%New holding127,600
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CHRS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CHRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herman Alan C.Chief Scientific Officer 2015-12-01Sell11,333$29.49-57.48view
Lanfear Dennis MPresident and CEO 2015-11-30Sell400$31.75-60.5view
Richards ChristosDirector 2015-11-13Sell15,000$27.49-54.38view
Herman Alan C.Chief Scientific Officer 2015-11-02Sell18,416$28.71-56.32view
Herman Alan C.Chief Scientific Officer 2015-10-01Sell4,250$18.98-33.93view
Herman Alan C.Chief Scientific Officer 2015-09-01Sell11,333$27.39-54.22view
Wahlstrom MatsDirector 2015-08-18Sell6,373$33.5-62.57view
Wahlstrom MatsDirector 2015-08-17Sell8,028$33.91-63.02view
Wahlstrom MatsDirector 2015-08-14Sell116,554$34.24-63.38view
Herman Alan C.Chief Scientific Officer 2015-08-03Sell14,166$34.83-64view

Quarterly/Annual Reports about CHRS:

News about CHRS:

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences to Present at Bloomberg Intelligence Healthcare Event on February 12th Feb 05 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 01 2016
Coherus Announces the Appointment of Jim Daly, Executive Chairman, Commercial Advisory Committee Feb 01 2016
Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints in... Feb 01 2016
Coherus Announces the Appointment of Jim Daly, Executive Chairman, Commercial Advisory Committee Feb 01 2016
Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints in... Feb 01 2016
Coverage initiated on Coherus BioSciences by Credit Suisse Jan 20 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2016
Coherus and Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy... Jan 11 2016
Coherus and Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy... Jan 11 2016
Coherus BioSciences to Present at J.P. Morgan Healthcare Conference on January 11 Jan 04 2016
Coherus BioSciences to Present at J.P. Morgan Healthcare Conference on January 11 Jan 04 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 21 2015
Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply... Dec 21 2015
Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply... Dec 21 2015
How Coherus Biosciences (CHRS) Stock Stands Out in a Strong Industry Dec 18 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events Dec 14 2015
Coherus BioSciences, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 11 2015
Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : December 10, 2015 Dec 10 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK